COPAXONE® is now approved in 52 countries worldwide, including the United States, Canada, Mexico, Australia, Israel and all European countries. In North America, COPAXONE® is marketed by
Teva Neuroscience, Inc., which is a subsidiary of
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). In Europe, COPAXONE® is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd.